| Description | CGP78850 is a potent and selective Grb2 SH2-phosphopeptide interaction antagonist that holds potential for cancer research. |
| In vitro | CGP78850 (0~100 μM; 90 minutes; MDA-MB-468 cells) reduces the amount of associated Grb2 protein in a dose-dependent manner[1]. CGP78850 blocks epidermal growth factor receptor (EGFR)-Grb2 and Shc-Grb2 interaction in living cells. CGP78850 inhibits MDA-MB-468 cells to form colonies in soft agar in a dose-dependent manner[1]. Western Blot Analysis[1]Cell Line: MDA-MB-468 cells Concentration: 0~100 μM Incubation Time: 90 minutes Result: Reduced the amount of associated Grb2 protein in a dose-dependent manner. |
| molecular weight | 723.764 |
| Molecular formula | C36H46N5O9P |
| CAS | 258326-83-9 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Gay B, et al. Selective GRB2 SH2 inhibitors as anti-Ras therapy. Int J Cancer. 1999;83(2):235-241. |